CN102451171B - Tindazole vaginal effervescent tablet and preparation method thereof - Google Patents
Tindazole vaginal effervescent tablet and preparation method thereof Download PDFInfo
- Publication number
- CN102451171B CN102451171B CN 201010520940 CN201010520940A CN102451171B CN 102451171 B CN102451171 B CN 102451171B CN 201010520940 CN201010520940 CN 201010520940 CN 201010520940 A CN201010520940 A CN 201010520940A CN 102451171 B CN102451171 B CN 102451171B
- Authority
- CN
- China
- Prior art keywords
- preparation
- tindazole
- recipe quantity
- effervescent tablet
- tartaric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 34
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 18
- 239000011975 tartaric acid Substances 0.000 claims abstract description 18
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 17
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 17
- 239000008101 lactose Substances 0.000 claims abstract description 17
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 17
- 239000011734 sodium Substances 0.000 claims abstract description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002245 particle Substances 0.000 claims abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000741 silica gel Substances 0.000 claims abstract description 9
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract 4
- 239000008107 starch Substances 0.000 claims abstract 4
- 235000019698 starch Nutrition 0.000 claims abstract 4
- 239000008187 granular material Substances 0.000 claims description 30
- 239000011230 binding agent Substances 0.000 claims description 22
- 238000005303 weighing Methods 0.000 claims description 20
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 16
- 229950005770 hyprolose Drugs 0.000 claims description 16
- 229960005053 tinidazole Drugs 0.000 claims description 16
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 229960001375 lactose Drugs 0.000 claims description 10
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract 2
- 238000005453 pelletization Methods 0.000 abstract 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 238000005187 foaming Methods 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 208000010362 Protozoan Infections Diseases 0.000 description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a tindazole vaginal effervescent tablet and a preparation method thereof. The tindazole vaginal effervescent tablet comprises the following components by weight: 0.2g of tindazole, 0.08-0.15g of tartaric acid, 0.10-0.15g of sodium bicarbonate, 0.15-0.25g of lactose, 0.08-0.16g of hydroxypropylcellulose, 0.05-0.1g of carboxyrnethyl starch sodium, 0.008-0.024g of polyvidone K30, 0.10-0.20g of purified water, 0.003-0.008g of polysorbate-80, talc powder of which the amount accounts for 1.0-3.0 percent of the total weight of particles and 0.5-2.0 percent of superfine silica gel powder of which the amount accounts for 0.5-2.0 percent of the total weight of the particles. The preparation method comprises the following steps of: pelletizing the tartaric acid and sodium bicarbonate respectively; pelletizing prepared acid source particles and gas source particles with 50 percent of main medicaments and auxiliary materials respectively; and uniformly mixing the obtained particles with additional auxiliary materials, and tableting. Compared with the prior art, the tindazole vaginal effervescent tablet has the advantages of easiness for operating, freeness from adhesion and avoidance of a splitting phenomenon in a tableting process, reasonable mixture ratio of an acid source and a gas source, unique preparation method, complete assurance that the foaming amount and external properties of a product are consistent with standard requirements, and avoidance of a package bulging phenomenon after package and within an effective period.
Description
Technical field:
The present invention relates to a kind of infusorian and most of anaerobe are had suppress or Tindazole vaginal effervescent tablet agent of killing action and preparation method thereof, belong to technical field of medicine.
Background technology:
Protozoan infection and anaerobic infection are common gynecological disease and frequently-occurring disease, and trichomonal vaginitis is a kind of common sexually transmitted disease, and women's sickness rate is 10%～25%, and etiology is trichomonal vaginitis.The sickness rate of sexually transmitted disease (STD) increases year by year in recent years, in the past simple whole body administration can not reach promising result to the vaginitis of anaerobe and protozoan infection, and oral administration and drug administration by injection, still have nauseating, vomiting, mouthful in the gastrointestinal reactions such as metallic taste, anorexia, abdomen disease.For better performance drug effect, the untoward reaction of avoiding the whole body administration to cause, in recent years, domestic external preparation research to this medicine was extensive rapidly.Especially Tindazole vaginal effervescent tablet agent, because design principle includes acid source and source of the gas for prescription, behind the vagina administration, moistening through the physiological vaginal secretions, slowly the effervescent disintegrate produces trickle and lasting bubble and forms foam, increased contacting of medicine and vagina and cervical mucosa, made the medicine can infiltrate mucosa gauffer deep.Compare effective in cure height with suppository, medicine is difficult for running off, and does not pollute the advantages such as clothing.
In the prior art, because prescription forms or also there is following shortcoming in technological problems: in the tabletting process sticking is arranged, sliver, the phenomenon such as mobility of particle is bad; After the low or packing of gas release and a swollen bag phenomenon arranged in the put procedure; Unilateral have phenomenons such as mottle and friability be defective.
Summary of the invention:
Purpose of the present invention is intended to overcome defects, a kind of Tindazole vaginal effervescent tablet and preparation method thereof is provided, have the tabletting process easy to operate, without sticking, without the sliver phenomenon, reasonable recipe, technique advanced person, under the prerequisite that the gas release that fully guarantees product, appearance character conformance with standard require, guaranteed after the packing and in effect duration without the generation of swollen bag phenomenon.
Technical scheme of the present invention is as follows:
Tindazole vaginal effervescent tablet, comprise principal agent and adjuvant, it is characterized in that every contains following component and parts by weight: tinidazole 0.2g, tartaric acid 0.08g～0.15g, sodium bicarbonate 0.10g～0.15g, lactose 0.15g～0.25g, hyprolose 0.08～0.16g, carboxymethylstach sodium 0.05g～0.1g, 30 POVIDONE K 30 BP/USP
300.008～0.024g, purified water 0.10～0.20g, Tween-80 0.003g～0.008g, Pulvis Talci account for 1.0～3.0% of particle weight, and micropowder silica gel accounts for 0.5～2.0% of particle weight.
Wherein tinidazole is active component, and tartaric acid, sodium bicarbonate are effervescent, and lactose is diluent, and hyprolose has the multiple actions such as diluent, binding agent, disintegrating agent concurrently, and carboxymethylstach sodium is disintegrating agent, 30 POVIDONE K 30 BP/USP
30Aqueous solution is binding agent, and Tween-80 is surfactant, and Pulvis Talci is lubricant, and differential silica gel is fluidizer.
The preparation method of Tindazole vaginal effervescent tablet of the present invention may further comprise the steps:
1) supplementary material is pulverized respectively, all crosses 80～120 mesh sieves, and is for subsequent use.
2) accurately take by weighing purified water, 30 POVIDONE K 30 BP/USP by recipe quantity
30, for subsequent use as binding agent after the Tween-80 dissolving.
3) accurately take by weighing tartaric acid, sodium bicarbonate respectively with the wet grain of an amount of system of the binding agent of above-mentioned preparation by recipe quantity, respectively at oven dry below 55 ℃, for subsequent use with 16 mesh sieve granulate.
4) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the tartaric acid granulate mix homogeneously that makes, with the wet grain of an amount of system of the binding agent of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
5) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the sodium bicarbonate particle mix homogeneously that makes, with the wet grain of an amount of system of the binding agent of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
6) with 4) with 5) granule of preparation and Pulvis Talci, the differential silica gel mix homogeneously of recipe quantity, detect granule content, it is heavy to calculate sheet, tabletting, packing and get final product.
The invention has the advantages that:
1) reasonable recipe of the present invention, technique uniqueness, overcome sticking in the prior art tabletting process, sliver, the shortcoming such as mobility of particle is bad, under the prerequisite that the gas release that fully guarantees product, appearance character conformance with standard require, guaranteed after the packing and in effect duration without the generation of swollen bag phenomenon.
2) design principle of the present invention includes acid source and source of the gas for prescription, behind the vagina administration, moistening through the physiological vaginal secretions, slowly the effervescent disintegrate produces trickle and lasting bubble and forms foam, increased contacting of medicine and vagina and cervical mucosa, made the medicine can infiltrate mucosa gauffer deep.Compare effective in cure height with suppository, medicine is difficult for running off, and does not pollute the advantages such as clothing.
3) the present invention has preferably therapeutical effect to the vaginitis of protozoan infection and anaerobic infection.
The specific embodiment:
Embodiment 1
Tindazole vaginal effervescent tablet, 1000 prescription and preparation method are as follows:
Prescription:
Tinidazole 200g
Tartaric acid 100g
Sodium bicarbonate 106g
Lactose 180g
Hyprolose 120g
Carboxymethylstach sodium 80g
PVP
K30 22g
Tween-80 5g
Purified water 160g
Pulvis Talci 1.0%
Silicon dioxide 0.6%
Make 1000
Preparation method:
1) supplementary material is pulverized respectively, all crosses 100 mesh sieves, and is for subsequent use.
2) accurately take by weighing purified water, 30 POVIDONE K 30 BP/USP by recipe quantity
30, for subsequent use as binding agent after the Tween-80 dissolving.
3) accurately take by weighing tartaric acid, sodium bicarbonate respectively with the wet grain of binding agent 18g, 24g system of above-mentioned preparation by recipe quantity, respectively at oven dry below 55 ℃, for subsequent use with 16 mesh sieve granulate.
4) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the tartaric acid granulate mix homogeneously that makes, with the wet grain of the binding agent 73g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
5) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the sodium bicarbonate particle mix homogeneously that makes, with the wet grain of the binding agent 72g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
6) with 4) with 5) granule of preparation and Pulvis Talci, the differential silica gel mix homogeneously of recipe quantity, detect granule content, it is heavy to calculate sheet, special-shaped stamping, packing and get final product.
Embodiment 2
Tindazole vaginal effervescent tablet, 1000 prescription and preparation method are as follows:
Prescription:
Tinidazole 200g
Tartaric acid 90g
Sodium bicarbonate 95g
Lactose 150g
Hyprolose 100g
Carboxymethylstach sodium 70g
PVP
K30 17g
Tween-80 4.5g
Purified water 153g
Pulvis Talci 1.0%
Silicon dioxide 0.6%
Make 1000
Preparation method:
1) supplementary material is pulverized respectively, all crosses 100 mesh sieves, and is for subsequent use.
2) accurately take by weighing purified water, 30 POVIDONE K 30 BP/USP by recipe quantity
30, for subsequent use as binding agent after the Tween-80 dissolving.
3) accurately take by weighing tartaric acid, sodium bicarbonate respectively with the wet grain of binding agent 16g, 21g system of above-mentioned preparation by recipe quantity, respectively at oven dry below 55 ℃, for subsequent use with 16 mesh sieve granulate.
4) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the tartaric acid granulate mix homogeneously that makes, with the wet grain of the binding agent 69g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
5) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the sodium bicarbonate particle mix homogeneously that makes, with the wet grain of the binding agent 68g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
6) with 4) with 5) granule of preparation and Pulvis Talci, the differential silica gel mix homogeneously of recipe quantity, detect granule content, it is heavy to calculate sheet, special-shaped stamping, packing and get final product.
Embodiment 3
Tindazole vaginal effervescent tablet, 1000 prescription and preparation method are as follows:
Prescription:
Tinidazole 200g
Tartaric acid 120g
Sodium bicarbonate 127g
Lactose 230g
Hyprolose 150g
Carboxymethylstach sodium 95g
PVP
K30 24g
Tween-80 6g
Purified water 176g
Pulvis Talci 1.0%
Silicon dioxide 0.6%
Make 1000
Preparation method:
1) supplementary material is pulverized respectively, all crosses 100 mesh sieves, and is for subsequent use.
2) accurately take by weighing purified water, 30 POVIDONE K 30 BP/USP by recipe quantity
30, for subsequent use as binding agent after the Tween-80 dissolving.
3) accurately take by weighing tartaric acid, sodium bicarbonate respectively with the wet grain of binding agent 21g, 28g system of above-mentioned preparation by recipe quantity, respectively at oven dry below 55 ℃, for subsequent use with 16 mesh sieve granulate.
4) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the tartaric acid granulate mix homogeneously that makes, with the wet grain of the binding agent 79g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
5) take by weighing tinidazole, lactose, hyprolose, the carboxymethylstach sodium of 1/2 recipe quantity and the sodium bicarbonate particle mix homogeneously that makes, with the wet grain of the binding agent 78g system of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate.
6) with 4) with 5) granule of preparation and Pulvis Talci, the differential silica gel mix homogeneously of recipe quantity, detect granule content, it is heavy to calculate sheet, special-shaped stamping, packing and get final product.
Claims (2)
1. Tindazole vaginal effervescent tablet is characterized in that its prescription counts by every: tinidazole 0.2g, tartaric acid 0.08g～0.15g, sodium bicarbonate 0.10g～0.15g, lactose 0.15g～0.25g, hyprolose 0.08g～0.16g, carboxymethyl starch sodium 0.05g～0.1g, 30 POVIDONE K 30 BP/USP
300.008g～0.024g, purified water 0.10g～0.20g, Tween-80 0.003g～0.008g, Pulvis Talci account for 1.0～3.0% of particle weight, and micropowder silica gel accounts for 0.5～2.0% of particle weight.
2. the preparation method of Tindazole vaginal effervescent tablet according to claim 1 is characterized in that may further comprise the steps:
1) supplementary material is pulverized respectively, all crosses 80～120 mesh sieves, and is for subsequent use;
2) accurately take by weighing purified water, 30 POVIDONE K 30 BP/USP by recipe quantity
30, for subsequent use as binding agent after the Tween-80 dissolving;
3) accurately take by weighing tartaric acid, sodium bicarbonate respectively with the wet grain of an amount of system of the binding agent of above-mentioned preparation by recipe quantity, respectively at oven dry below 55 ℃, for subsequent use with 16 mesh sieve granulate;
4) take by weighing tinidazole, lactose, hyprolose, the carboxymethyl starch sodium of 1/2 recipe quantity and the tartaric acid granulate mix homogeneously that makes, with the wet grain of an amount of system of the binding agent of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate;
5) take by weighing tinidazole, lactose, hyprolose, the carboxymethyl starch sodium of 1/2 recipe quantity and the sodium bicarbonate particle mix homogeneously that makes, with the wet grain of an amount of system of the binding agent of above-mentioned preparation, in oven dry below 55 ℃, with 12 mesh sieve granulate;
6) with 4) with 5) granule of preparation and Pulvis Talci, the micropowder silica gel mix homogeneously of recipe quantity, detect granule content, it is heavy to calculate sheet, tabletting, packing and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010520940 CN102451171B (en) | 2010-10-14 | 2010-10-14 | Tindazole vaginal effervescent tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010520940 CN102451171B (en) | 2010-10-14 | 2010-10-14 | Tindazole vaginal effervescent tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102451171A CN102451171A (en) | 2012-05-16 |
| CN102451171B true CN102451171B (en) | 2013-10-30 |
Family
ID=46035115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010520940 Active CN102451171B (en) | 2010-10-14 | 2010-10-14 | Tindazole vaginal effervescent tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102451171B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112220763A (en) * | 2020-10-21 | 2021-01-15 | 上海桓华制药有限公司 | Terbinafine hydrochloride effervescent tablet and use method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109330983A (en) * | 2018-07-27 | 2019-02-15 | 江苏中天药业有限公司 | A kind of vagina effervescence and preparation method thereof |
| CN113230226A (en) * | 2021-05-28 | 2021-08-10 | 丽珠集团丽珠制药厂 | Tinidazole tablet and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726910A (en) * | 2005-07-22 | 2006-02-01 | 福寿堂制药有限公司 | Effervescence tablet of miconazole nitrate for vagina and preparation technique |
-
2010
- 2010-10-14 CN CN 201010520940 patent/CN102451171B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726910A (en) * | 2005-07-22 | 2006-02-01 | 福寿堂制药有限公司 | Effervescence tablet of miconazole nitrate for vagina and preparation technique |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112220763A (en) * | 2020-10-21 | 2021-01-15 | 上海桓华制药有限公司 | Terbinafine hydrochloride effervescent tablet and use method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102451171A (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181320B (en) | Dyer's woad root vitamin C effervescent formulation | |
| CN101099729B (en) | Oral solid preparation containing ambroxol hydrochloride and salbutamol active components | |
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN101129346A (en) | Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same | |
| CN101732342B (en) | Oral rehydration salt effervescent tablet and its application | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| CN102451171B (en) | Tindazole vaginal effervescent tablet and preparation method thereof | |
| CN101564402A (en) | Rehabilitation new dispersing tablet and preparation method thereof | |
| CN103120652B (en) | Phloroglucin orally disintegrating tablet and preparation method thereof | |
| CN101732312A (en) | Huperzine A oral formulation and a preparation method thereof | |
| CN103393612B (en) | Preparation method for enalapril maleate orally disintegrating tablets | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| WO2015005241A1 (en) | Ultrafast-disintegrating tablet and method for manufacturing same | |
| CN101584703B (en) | Pharmaceutical composition for treating colpitis and preparation method thereof | |
| CN108136035A (en) | Exceed the speed limit disintegrating tablet and preparation method thereof | |
| CN105213342A (en) | Ezetimibe sheet | |
| CN101912373A (en) | Stable cefeclor dispersible tablet and preparation method thereof | |
| CN100579516C (en) | A kind of vaginal effervescent tablet composition containing solid lipid | |
| CN100522175C (en) | Sustained release tablet of oleanolic acid and its preparation method | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN101732725B (en) | Composition for speeding up disintegration of tablet and application thereof | |
| CN102440969A (en) | A kind of ganoderma acid monomer T tablet and preparation method thereof | |
| CN101152187A (en) | Eplerenone pharmaceutical composition | |
| CN107320440B (en) | Sulforaphane-containing gastric retention composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 274500 the Yellow River Road, Shandong County, Dongming Applicant after: Shandong Fangming Pharmaceutical Group Co., Ltd. Address before: 274500 the Yellow River Road, Shandong County, Dongming Applicant before: Shandong Fangming Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG FANGMING PHARMACEUTICAL CO., LTD. TO: SHANDONG FANGMING PHARMACEUTICAL GROUP CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |